LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Ocular Therapeutix Inc

Closed

SectorHealthcare

12.81 0.47

Overview

Share price change

24h

Current

Min

12.76

Max

12.86

Key metrics

By Trading Economics

Income

-3.8M

-68M

Sales

2.8M

13M

Profit margin

-503.856

Employees

274

EBITDA

146K

-64M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+35.68% upside

Dividends

By Dow Jones

Next Earnings

13 Nov 2025

Market Stats

By TradingEconomics

Market Cap

244M

2.2B

Previous open

12.34

Previous close

12.81

News Sentiment

By Acuity

75%

25%

343 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Ocular Therapeutix Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Sept 2025, 22:41 UTC

Major Market Movers

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 Sept 2025, 16:04 UTC

Major Market Movers

Upexi Shares Climb on Solana Gains

12 Sept 2025, 15:03 UTC

Major Market Movers

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

13 Sept 2025, 08:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

12 Sept 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

12 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 Sept 2025, 20:09 UTC

Earnings

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 Sept 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 Sept 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 Sept 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 Sept 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 Sept 2025, 18:38 UTC

Market Talk
Earnings

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 Sept 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 Sept 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 Sept 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 Sept 2025, 16:22 UTC

Earnings

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 Sept 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 Sept 2025, 16:19 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 Sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12 Sept 2025, 16:11 UTC

Earnings

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 Sept 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 Sept 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 Sept 2025, 15:07 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 Sept 2025, 14:34 UTC

Market Talk

Russia Sanctions Put Bid Back in Oil -- Market Talk

12 Sept 2025, 14:10 UTC

Market Talk

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12 Sept 2025, 13:58 UTC

Market Talk

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12 Sept 2025, 13:58 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12 Sept 2025, 13:57 UTC

Earnings

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12 Sept 2025, 13:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 Sept 2025, 13:56 UTC

Market Talk

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

Peer Comparison

Price change

Ocular Therapeutix Inc Forecast

Price Target

By TipRanks

35.68% upside

12 Months Forecast

Average 17.38 USD  35.68%

High 21 USD

Low 14 USD

Based on 9 Wall Street analysts offering 12 month price targets forOcular Therapeutix Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

9

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

6.97 / 7.62Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

343 / 371 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
help-icon Live chat